

1 **A Phase II study to evaluate the safety and efficacy of prasinezumab in early**
2 **Parkinson's disease (PASADENA): rationale, design and baseline data**

3 Gennaro Pagano^{1*}, Frank G Boess¹, Kirsten I Taylor^{1,2}, Benedicte Ricci³, Brit Mollenhauer^{4,5},
4 Werner Poewe⁶, Anne Boulay⁷, Judith Anzures-Cabrera⁸, Annamarie Vogt¹, Maddalena
5 Marchesi³, Anke Post⁹, Tania Nikolcheva¹⁰, Gene G Kinney¹¹, Wagner M Zago¹¹, Daniel K
6 Ness¹¹, Hanno Svoboda¹, Markus Britschgi¹, Susanne Ostrowitzki¹⁰, Tanya Simuni¹²,
7 Kenneth Marek¹³, Martin Koller¹¹, Jeff Sevigny¹⁴, Rachelle Doody¹⁰, Paulo Fontoura¹⁰, Daniel
8 Umbricht¹, Azad Bonni¹, PASADENA Investigators and Prasinezumab Study Group

- 9 1. Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases
10 Discovery and Translational Area, Roche Innovation Center, F. Hoffmann-La Roche Ltd, Basel,
11 Switzerland;
12 2. Faculty of Psychology, University of Basel, Basel, Switzerland;
13 3. Roche Pharma Research and Early Development (pRED), Pharmaceutical Sciences, Roche
14 Innovation Center, F. Hoffmann-La Roche Ltd, Basel, Switzerland;
15 4. Paracelsus-Elena-Klinik, Kassel, Germany;
16 5. Department of Neurology, University Medical Center Göttingen, Göttingen, Germany;
17 6. Department of Neurology, Innsbruck Medical University, Innsbruck, Austria;
18 7. Idorisa Pharmaceuticals Ltd, Allschwil, Switzerland;
19 8. Roche Products Ltd, Welwyn Garden City, UK;
20 9. Feetme SAS, Paris, France;
21 10. F. Hoffmann-La Roche Ltd, Basel, Switzerland;
22 11. Prothena Biosciences Inc, South San Francisco, CA, USA;
23 12. Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL,
24 USA;
25 13. Institute for Neurodegenerative Disorders, New Haven, CT, USA;
26 14. Prevail Therapeutics, New York, USA.

27 *** Correspondence:**

28 Corresponding author: Gennaro Pagano MD, PhD
29 Expert Medical Director & Group Leader in Neuroscience and Rare Diseases
30 Roche Pharma Research and Early Development (pRED)
31 F. Hoffmann-La Roche Ltd
32 Basel, Switzerland
33 **Email:** gennaro.pagano@roche.com

34 **PASADENA investigators:** Claudia Altendorf, Chareyna Anandan, Giulia Andrews, Solène Ansquer,
35 Raphaelle Arrouasse, Sana Aslam, Jean-Philippe Azulay, Jeanette Baker, Ernest Balaguer Martinez,
36 Shadi Barbu, Kara Bardram, Danny Bega, Helena Bejr-Kasem Marco, Isabelle Benatru, Eve
37 Benchetrit, Felix Bernhard, Amir Besharat, Sagari Bette, Amelie Bichon, Andrew Billnitzer, Sophie
38 Blondeau, Thomas Boraud, Freiderike Borngräber, James Boyd, Kathrin Brockmann, Matthew
39 Brodsky, Ethan Brown, Christof Bruecke, Fabienne Calvas, Monica Canelo, Federico Carbone, Claire
40 Carroll, Laura Casado Fernandez, Catherine Cassé-Perrot, Anna Castrioto, Helene Catala, Justine
41 Chan, Samia Cheriet, Anthony Ciabarra, Joseph Classen, Juliana Coleman, Robert Coleman,
42 Yaroslau Compta, Anne-Gaëlle Corbillé, Jean-Christophe Corvol, Mariana Cosgaya, Nabila
43 Dahodwala, Philippe Damier, Elodie David, Thomas Davis, Marissa Dean, Berengere Debilly, Janell
44 DeGiorgio, Andres Deik, Laure Delaby, Marie-Helene Delfini, Pascal Derkinderen, Philipp Derost,
45 Maria de Toledo, Lisa Deuel, Ann Marie Diaz-Hernandez, Cameron Dietiker, Karina Dimenshteyn,
46 Julio Dotor, Franck Durif, Jens Ebentheuer, Karla Maria Eggert, Sara Eichau Madueño, Claudia
47 Eickhoff, Aaron Ellenbogen, Philipp Ellmerer, Ines Esparragosa Vazquez, Alexandre Eusebio,
48 Siobhan Ewert, John Fang, Danielle Feigenbaum, Frederique Fluchere, Alexandra Foubert-Samier,
49 Marie Fournier, Anne Fradet, Valerie Fraix, Samuel Frank, Franca Fries, Monique Galitzky, Marisol
50 Gallardó Pérez, Jose Manuel Garcia Moreno, Carmen Gasca, Thomas Gasser, Joyce Gibbons,
51 Caroline Giordana, Alicia Gonzalez Martinez, Ira Goodman, Arantza Gorospe, Marie Goubeaud,
52 David Grabli, Mangone Graziella, Stephan Grimaldi, Jeffrey Gross, Raquel Guimaraes-Costa,
53 Andreas Hartmann, Christian Hartmann, Travis Hassell, Robert Hauser, Antonio Hernandez, Jorge
54 Hernandez-Vara, Guenter Hoeglinger, Christian Homedes, Andrea Horta-Barba, Jean-Luc Houeto,
55 Julius Huebl, Jennifer Hui, Stuart Isaacson, Joseph Jankovic, Annette Janzen, Junior Jauregui,
56 Jocelyne Jiao, Maria Jose Marti Domenech, Xavier Joseph, Srinath Kadimi, Pat Kaminski, Silja
57 Kannenberg, Jan Kassubek, Maya Katz, Kevin Klos, Shannon Klos, Christopher Kobet, Jennifer
58 Koeber, Patricia Krause, Andrea Kuehn, Jaime Kulisevsky Bojarsky, Rajeev Kumar, Martin Kunz,
59 Lille Kurvits, Kimberly Kwei, Simon Laganiere, Brice Laurens, Johannes Levin, Oren Levy, Peter
60 LeWitt, Gurutz Linazasoro Cristóbal, Irene Litvan, Karlo Lizarraga, Katherine Longardner, Rocio
61 Lopez, Lydia Lopez Manzanares, Sara Lucas del Pozo, Maria Rosario Luquin Puido, Nijee Luthra,
62 Kelly Lyons, Sylvia Maass, Gerrit Machetanz, Yolanda Macias, David Maltete, Jorge Uriel Manez
63 Miro, Louise-Laure Mariani, Juan Marin, Kathrin Marini, Ana Marques, Gloria Marti, Maria Jose Marti
64 Domenech, Saul Martinez, Wassilios Meissner, Sara Meoni, Brit Mollenhauer, Dunia Mon Martinez,
65 Johnson Moon, Elena Moro, Peter Morrison, Christoph Muehlberg, Manpreet Multani, Christine
66 Murphy, Anthony Nicholas, Rajesh Pahwa, Antonio Palasi, Heidi Pape, Neepa Patel, Prity Patel,
67 Marina Peball, Elizabeth Peckham, Terry Peery, Rafael Perez, Jesus Perez, Alisa Petit, Elmar
68 Pinkhardt, Werner Poewe, Elsa Pomies, Cecile Preterre, Joseph Quinn, Olivier Rascol, Philippe
69 Remy, Irene Richard, Benjamin Roeben, Emily Ruether, Jost-Julian Rumpf, David Russell, Hayet
70 Salhi, Daniela Samaniego-Toro, Alexandra Samier-Foubert, Antonio Sanchez, Emmanuelle Schmitt,
71 Alfons Schnitzler, Oliver Schorr, Julie Schwartzbard, Kerstin Schweyer, Klaus Seppi, Victoria Sergio,
72 Holly Shill, Andrew Siderowf, Tanya Simuni, Umberto Spampinato, Ashok Sriram, Natividad Stover,
73 Caroline Tanner, Arjun Tarakad, Carolyn Taylor, Claire Thalamus, Thomas Toothaker, Nadege Van
74 Blercom, Nora Vanegas-Arrogave, Lydia Vela, Sylvian Vergnet, Tiphaine Vidal, Jonathan Voeglein,
75 Ryan Walsh, Cheryl Waters, Mirko Wegscheider, Endy Weidinger, Caroline Weill, Gregor Wenzel,
76 Tatiana Witjas, Isabel Wurster, Brenton Wright, Milan Zimmermann, Rafael Zuzuarregui.

77 **Prasinezumab Study Group:** Markus Abt, Atieh Bamdadian, Teresa Barata, Nicholas Barbet, Sara
78 Belli, Frank Boess, Azad Bonni, Edilio Borroni, Anne Boulay, Markus Britschgi, Jerome Chague,
79 Valerie Cosson, Christian Czech, Dennis Deptula, Cheikh Diack, Rachele Doody, Juergen Dukart,
80 Giulia D'Urso, Sebastian Dziadek, Hannah Eddleston, Chris Edgar, Laurent Essieux, Morgan Farrell,
81 Rebecca Finch, Paulo Fontoura, Waltraud Gruenbauer, Andrea Hahn, Stefan Holiga, Michael Honer,
82 Shirin Jadidi, Kelly Johnson-Wood, Markus Keller, Timothy Kilchenmann, Martin Koller, Thomas
83 Kremer, Thomas Kustermann, Claire Landsdall, Michael Lindemann, Florian Lipsmeier, Cecile Luzy,
84 Marianne Manchester, Maddalena Marchesi, Ferenc Martenyi, Meret Martin-Facklam, Katerina
85 Mironova, Annabelle Monnet, Emma Moore, Daniel K Ness, Markus Niggli, Tania Nikolcheva,
86 Susanne Ostrowitzki, Gennaro Pagano, Benedicte Passmard, Agnes Poirier, Anke Post, Megana
87 Prasad, Nathalie Pross, Tiffany Quock, Benedicte Ricci, Ellen Rose, Christoph Sarry, Christine
88 Schubert, Dennis Selkoe, Jeff Sevigny, Kaycee Sink, Hannah Staunton, Tim Steven, Alexander
89 Strasak, Hanno Svoboda, Kirsten Taylor, Radhika Tripuraneni, Dylan Trundell, Daniel Umbricht,
90 Lynne Verselis, Annamarie Vogt, Ekaterina Volkova-Volkmar, Cornelia Weber, Silke Weber, Wagner
91 Zago.

92 **Abstract (350/350 words, excluding subheadings)**

93 **Background**

94 Currently available treatments for Parkinson's disease (PD) do not slow clinical progression
95 nor target alpha-synuclein, the main pathology associated with the disease.

96 **Objective**

97 The study objective was to evaluate the efficacy and safety of prasinezumab, a humanized
98 monoclonal antibody that binds aggregated alpha-synuclein, in individuals with early PD.
99 The study rationale, design, and baseline characteristics of enrolled subjects are presented
100 here.

101 **Methods**

102 The PASADENA study is a multicenter, randomized, double-blind, placebo-controlled
103 treatment study. Individuals with early PD, recruited across the US and Europe, received
104 monthly intravenous doses of prasinezumab (1500 mg or 4500 mg) or placebo for a 52-week
105 period (Part 1), followed by a 52-week extension (Part 2) in which all participants received
106 active treatment. Key inclusion criteria were: aged 40–80 years; Hoehn & Yahr (H&Y) Stage
107 I or II; time from diagnosis ≤ 2 years; having bradykinesia plus one other cardinal sign of PD
108 (e.g. resting tremor, rigidity); DAT-SPECT imaging consistent with PD; and either treatment
109 naïve or on a stable monoamine oxidase B (MAO-B) inhibitor dose. Study design
110 assumptions for sample size and study duration were built using a patient cohort from the
111 Parkinson's Progression Marker Initiative (PPMI). In this report, baseline characteristics are
112 compared between the treatment-naïve and MAO-B inhibitor-treated PASADENA cohorts
113 and between the PASADENA and PPMI populations.
114

115 **Results**

116 Of the 443 patients screened, 316 were enrolled into the PASADENA study between June
117 2017 and November 2018, with an average age of 59.9 years and 67.4% being male. The
118 mean time from diagnosis at baseline was 10.11 months, with 75.3% in H&Y Stage II.
119 Baseline motor and non-motor symptoms (assessed using Movement Disorder Society –
120 Unified Parkinson's Disease Rating Scale [MDS-UPDRS]) were similar in severity between
121 the MAO-B inhibitor-treated and treatment-naïve PASADENA cohorts (MDS-UPDRS Total
122 score [standard deviation (SD)]; 30.21 [11.96], 32.10 [13.20], respectively). The overall
123 PASADENA population (63.6% treatment naïve and 36.4% on MAO-B inhibitor) also showed
124 a similar severity in MDS-UPDRS scores (e.g. MDS-UPDRS Total score [SD]; 31.41 [12.78],
125 32.63 [13.04], respectively) to the PPMI cohort (all treatment naïve).

126 **Conclusions**

127 The PASADENA study population is suitable to investigate the potential of prasinezumab to
128 slow disease progression in individuals with early PD.

129 **Trial Registration:** NCT03100149

130 **Total word count: 6086/12000**
131 **4 figures and 1 table**

132 **Introduction**

133 There is a high medical need to develop long-lasting therapies that can affect the underlying
134 cause of Parkinson's disease (PD) and, therefore, slow disease progression (1-3). Currently
135 available treatments have powerful symptomatic effects, particularly on motor symptoms, but
136 they do not address the pathological processes underlying the disease and do not prevent or
137 slow clinical decline (2, 3). With the progressive loss of dopaminergic and non-dopaminergic
138 neurons and synapses, available therapies gradually become less effective at controlling PD
139 motor symptoms (4-6). Individuals with PD will invariably develop motor complications and
140 lose their autonomy, adversely affecting their quality of life and placing a significant burden
141 on caregivers, family members and healthcare systems (7-9). Despite the high prevalence
142 and impact of non-motor symptoms on the quality of life of individuals with PD, treatment
143 options for these symptoms are limited (10). A therapy that targets the underlying cause of
144 the disease has the potential to slow motor progression as well as address non-motor
145 symptoms (11, 12).

146
147 *Postmortem* findings suggest that the loss of dopaminergic neurons is accompanied spatially
148 and temporally by the progressive development of intraneuronal Lewy pathology, which is a
149 neuropathological hallmark of PD in distinct brain regions (13-16). Lewy pathology is
150 abnormally enriched in alpha-synuclein, a protein with key functions in neurons (17).
151 Although the etiology of PD is yet to be elicited, the spatio-temporal association between
152 Lewy pathology and neurodegeneration, together with evidence from *in vitro* and *in vivo*
153 models, suggests that pathologically aggregated forms of alpha-synuclein may contribute to
154 axonal and neuronal damage, formation of Lewy pathology and consequent neuronal loss
155 and disease progression (17-21).

156
157 Preclinical findings in cellular and animal models also support the hypothesis that certain
158 aggregated forms of alpha-synuclein may be taken up by neurons and may induce the
159 formation of intracellular alpha-synuclein inclusions in PD (19, 22-24). The appearance of
160 intraneuronal inclusions throughout the central and peripheral nervous systems may arise
161 upon propagation of Lewy pathology from neuron to neuron in a concerted manner by
162 extracellular transfer of aggregated alpha-synuclein (20, 25-27).

163
164 Clinical evidence also supports the hypothesis that alpha-synuclein is a key driver in the
165 etiology of PD. For instance, both missense mutations (28) and increased production of
166 alpha-synuclein due to duplication or triplication of the synuclein gene (*SNCA*) (29-31) cause
167 early-onset autosomal dominant PD, with virtually 100% penetrance (32). Although the exact
168 patho-physiological mechanism in these genetic causes remains unclear, aggregation of
169 alpha-synuclein due to missense mutation or overexpression is supposed to drive disease
170 onset and progression (33). Direct transfer of aggregated alpha-synuclein from neuron to
171 neuron has not been directly observed in humans. However, embryonic dopaminergic
172 neurons transplanted into the striatum of individuals with PD harbored inclusions reminiscent
173 of Lewy pathology approximately a decade after initial grafting (34, 35) which, together with
174 replicated observations in animal models (22, 23), suggests the possibility of intercellular
175 propagation of Lewy pathology. In support of a caudo-rostral propagation of Lewy pathology,
176 molecular imaging studies demonstrate damage or dysfunction of noradrenergic and
177 serotonergic pathways prior to the dopaminergic pathways in prodromal idiopathic and
178 *SNCA* genetic PD (36, 37).

179
180 The growing understanding of the role of alpha-synuclein in the development of Lewy
181 pathology and the pathogenesis of PD support the rationale that targeting alpha-synuclein
182 may have therapeutic potential (38). Preclinical *in vivo* models of alpha-synucleinopathy,
183 such as transgenic mice overexpressing wild-type human alpha-synuclein or that develop
184 pathology upon intracerebral injection of aggregated recombinant alpha-synuclein, are
185 valuable when studying drug mechanisms targeting alpha-synuclein. These models may

186 help identify the downstream mode of action of therapeutic compounds. Indeed,
187 neuropathological and behavioral deterioration in various mouse models of alpha-synuclein
188 pathology was shown to be ameliorated by treatment with monoclonal antibodies binding to
189 aggregated alpha-synuclein (12, 39-43).

190
191 Prasinezumab (previously known as RO7046015/PRX002) is an investigational, humanized
192 monoclonal immunoglobulin G1 antibody directed against an epitope in the carboxyl
193 terminus of human alpha-synuclein (11, 39, 40, 44). It binds to human aggregated alpha-
194 synuclein with a high affinity and avidity (11, 39, 40). Preclinical pharmacologic studies to
195 evaluate efficacy and potency of the murine form of prasinezumab (9E4) were performed in
196 two transgenic mouse lines featuring alpha-synuclein aggregation disorders: Line D and Line
197 61 mice. The mice were treated with weekly intraperitoneal administration of murine version
198 9E4 over 5–6 months and showed reduced neuronal and synaptic loss and a reduction in
199 intraneuronal build-up of alpha-synuclein pathology (measured as alpha-synuclein inclusions
200 in cortical and subcortical regions), reduction of gliosis, and an improvement in both
201 cognitive and motor behaviors (12, 39-41).

202
203 Although blockade of cell-to-cell transmission of alpha-synuclein by extracellular
204 neutralization of pathogenic species has been proposed as the main mechanism of action of
205 prasinezumab, evidence also supports potential clearance of alpha-synuclein species *via* the
206 lysosomal pathway (12). Together, these preclinical data support the therapeutic potential of
207 prasinezumab in slowing the progression of PD.

208
209 In a Phase I single-ascending-dose study in healthy volunteers and a Phase I multiple-
210 ascending-dose study in individuals with PD, prasinezumab was safe, able to penetrate the
211 blood–brain barrier (measured in the cerebrospinal fluid), and showed robust peripheral
212 binding to alpha-synuclein (11, 44). Peripheral binding, measured as the lowering of
213 circulating, free (unbound) serum alpha-synuclein, occurred within 1 hour of administration of
214 prasinezumab and was maintained for longer durations with higher doses of prasinezumab
215 (11). Results also demonstrated a dose-dependent increase of prasinezumab in
216 cerebrospinal fluid concentration, which was approximately 0.3% relative to serum across all
217 dose groups (11). Prasinezumab has a high binding affinity/avidity to aggregated alpha-
218 synuclein vs. monomeric alpha-synuclein and, together with the observed cerebrospinal fluid
219 concentrations achieved, it is predicted that >90% of aggregated alpha-synuclein will be
220 engaged in the brain of individuals with PD at doses ≥ 1500 mg (11). The 1500 mg and 4500
221 mg doses were selected as both were expected to saturate the target in a Phase II study in
222 individuals with early PD.

223 Here we report the study rationale, design, and baseline patient characteristics of
224 PASADENA, a Phase II clinical trial testing efficacy and safety of prasinezumab in
225 individuals with early PD. The study design and assumptions for sample size and study
226 duration were built, in part, using a patient cohort from the Parkinson's Progression Markers
227 Initiative (PPMI) study group. The PPMI is a landmark, global, observational clinical study of
228 individuals with PD designed to comprehensively evaluate cohorts of significant interest
229 using advanced imaging, biological sampling and clinical and behavioral assessments to
230 identify biomarkers of PD progression (45). We compared the baseline characteristics of the
231 treatment-naïve and the monoamine oxidase B (MAO-B) inhibitor-treated cohorts of the
232 PASADENA population. We also compared the baseline characteristics of the total
233 PASADENA population with the characteristics of a subset of individuals with early PD
234 enrolled in the PPMI study, which was selected using similar inclusion criteria to the
235 PASADENA study (46).

236 **Methods**

237 Study design

238 The Phase II study of Anti alpha-Synuclein Antibody in Early Parkinson's disease
239 (PASADENA) to evaluate the safety and efficacy of prasinezumab (NCT03100149) is an
240 multicenter, randomized, double-blind, placebo-controlled study across approximately 60
241 sites in the United States, France, Austria, Germany and Spain. The study was designed to
242 evaluate the efficacy and safety of intravenous prasinezumab (received every 4 weeks) in
243 participants with early-stage PD (Hoehn and Yahr [H&Y] Stages I–II, time since diagnosis \leq 2
244 years).

245
246 The study consists of two parts: a 52-week, double-blind, placebo-controlled treatment
247 period (Part 1), followed by a 52-week extension period during which all participants
248 received active treatment but remained blinded to original dose allocation (Part 2) (**Figure**
249 **1**). A 12-week safety follow-up was mandatory for all participants, regardless of whether
250 cessation of treatment occurred after Part 1 or Part 2.

251
252 In Part 1, participants were randomized with a 1:1:1 allocation ratio to either placebo, a high
253 dose (4500 mg for body weight \geq 65 kg; 3500 mg for body weight $<$ 65 kg) or a low dose
254 (1500 mg for all body weights) of prasinezumab. Body weight has an effect on clearance
255 (and volume of distribution) such that exposure increases in patients with lower body weight.
256 Therefore, the use of an approximately 25% lower dose in participants with lower body
257 weight ($<$ 65 kg) is implemented at high doses where there is an increased risk for infusion-
258 related reactions. To reduce the risk of infusion-related reactions, participants in the high-
259 dose group received a 2000 mg intravenous infusion on Day 1 followed by an up-titration to
260 the full dose on Day 28 which they then received every 4 weeks. In addition, the first three
261 study treatment infusions (irrespective of treatment allocation) were prolonged to 2 hours
262 and were preceded by pre-medication with non-sedating antihistamine and acetaminophen
263 (11). Randomization was stratified by sex, age group ($<$ 60 years vs. \geq 60 years) and use of
264 MAO-B inhibitor at baseline (yes vs. no).

265
266 Participants from Part 1 were eligible to continue to Part 2 provided dopamine transporter
267 single-photon emission computerized tomography (DaT-SPECT) and magnetic resonance
268 imaging (MRI) scans had been completed at screening and Week 52, and participants had
269 received at least 10 doses of study treatment (placebo or prasinezumab) during Part 1.

270
271 In Part 2, participants randomized to treatment with prasinezumab in Part 1 remained on the
272 same dose for the duration of Part 2. Those participants initially randomized to placebo were
273 re-randomized to either 1500 mg or 4500 mg prasinezumab using a 1:1 allocation ratio.
274 Randomization was stratified by dopaminergic therapy since start of study (yes vs. no), sex,
275 age group at start of study ($<$ 60 years vs. \geq 60 years) and use of MAO-B inhibitor at baseline
276 (yes vs. no).

277
278 If symptomatic treatment was initiated during Part 1, investigators were required to record
279 the reason(s) and the type and dose of symptomatic PD treatment prescribed. Participants
280 who initiated symptomatic PD treatment could then continue in the study, as per their regular
281 scheduled study visits. For participants who started dopaminergic treatment (levodopa or
282 dopamine agonist), the Movement Disorder Society – Unified PD Rating Scale (MDS-
283 UPDRS) including Part IV (motor assessment while on dopaminergic treatment) and digital
284 biomarker in-clinic assessments at subsequent visits were performed in an “Off” state, i.e.
285 patients had not received levodopa since the previous evening ($>$ 8 hours prior). The MDS-
286 UPDRS Part III (motor assessment) was repeated at least 1 hour after receiving levodopa in
287 the clinic (while patients are in an “On” state), along with digital biomarker in-clinic
288 assessments.

289 *Study population*

290

291 The inclusion and exclusion criteria were developed to select an early PD population with a
292 measurable and precitable rate of progression over a 1-year period.

293

294 Key inclusion criteria included: idiopathic PD with bradykinesia and one of the other cardinal
295 signs of PD (resting tremor, rigidity) and no other known or suspected cause of PD; aged
296 40–80 years; a DaT-SPECT consistent with PD; body weight range of ≥ 45 kg to ≤ 110 kg and
297 a body mass index of 18 to 34 kg/m²; and either treatment naïve or on a stable dose of a
298 MAO-B inhibitor for at least 90 days.

299

300 Key exclusion criteria included: medical history indicating a Parkinson syndrome other than
301 idiopathic PD; known carriers of certain familial PD genes (*Parkin*, *PINK1*, *DJ1*); Mini Mental
302 State Examination (MMSE) ≤ 25 ; use of any of the following: catechol-O-methyl transferase
303 inhibitors (entacapone, tolcapone), amantadine or anticholinergics, or dopaminergic
304 medication (levodopa and both ergot and non-ergot [pramipexole, ropinirole, rotigotine]
305 dopamine agonists) for more than a total of 60 days or within 60 days of baseline and prior
306 participation in any prasinezumab study.

307

308 A full list of inclusion and exclusion criteria can be found in Table 1 and Table 2 in the
309 Supplementary Materials.

310

311

312 *Objectives and endpoints*

313 Clinical assessments performed at baseline and at different study visits are summarized in
314 **Figure 2** and **Figure 3**. A full list of endpoints is available online in the PASADENA study
315 protocol (NCT03100149) (47).

316

317 *Primary endpoint*

318 The primary objective of the study was to assess the efficacy of prasinezumab 1500 mg and
319 4500 mg vs. placebo at Week 52 in enrolled participants. The primary endpoint was the
320 change from baseline at Week 52 in MDS-UPDRS Total score (sum of Parts I, II and III) vs.
321 placebo.

322

323 *Secondary endpoints*

324 The effects of prasinezumab 1500 mg and 4500 mg vs. placebo at Week 52 on MDS-
325 UPDRS Part IA, Part IB, Part I total, Part II total, Part III total and Part III subscores
326 (bradykinesia, rigidity, resting tremor and axial symptoms) were included as secondary
327 endpoints. Part I assessed non-motor experiences of daily living, with Part IA focused on
328 complex behaviors (cognitive impairment, hallucinations and psychosis, etc.) and Part IB
329 focused on non-motor experiences (sleep and urinary problems, constipation, pain, etc.).
330 Part II assessed motor experiences of daily living (eating, dressing, handwriting, getting out
331 of bed, etc.) and Part III assessed motor signs of PD (speech, finger tapping, bradykinesia,
332 gait and freezing, etc.) (48). Part IA and Part III were administered by the study investigator,
333 and Part IB and Part II were completed by the participant.

334

335 Other secondary endpoints included; Montreal Cognition Assessment (MoCA) Total score;
336 Clinical Global Impression of Improvement (CGI-I); Patient Global Impression of Change
337 (PGI-C); DaT-SPECT in the ipsilateral (to the clinically dominant side) putamen; Schwab and
338 England Activity of Daily Living (SE-ADL) score; time to worsening in motor or non-motor
339 symptoms (increase of ≥ 3 points in MDS-UPDRS Part I or MDS-UPDRS Part II); time to start
340 of dopaminergic PD treatment (levodopa or dopamine agonists); and safety, tolerability,

341 immunogenicity, and pharmacokinetics (PK) of prasinezumab. Safety and tolerability were
342 assessed for up to 104 weeks, with or without dopaminergic treatment. PK of prasinezumab
343 was assessed using population PK modeling.

344

345 *Exploratory endpoints*

346 Exploratory endpoints of this study included: MDS-UPDRS Part III subscores determined by
347 independent central raters (using video recordings to address consistency and accuracy in
348 the trained site raters), imaging analysis of striatum, caudate and putamen (average,
349 ipsilateral and contralateral) for DaT-SPECT binding ratio values, and the change from
350 baseline on a sensor-based measure derived from Roche PD Mobile Application v2 digital
351 biomarkers (49) (smartphone and wrist-worn wearable) assessments (see **Figure 4** for an
352 overview of the remote monitoring tests). The analyses of primary and secondary endpoints
353 were also repeated, with the results for the two prasinezumab 1500 mg and 4500 mg pooled
354 doses vs. placebo, as a pre-specified exploratory analysis.

355

356 A full list of endpoints exploratory endpoints is included in Supplementary Table 3.

357

358 *PASADENA Digital Motor Score*

359 Summary scores of sensor data from digital health technology tools should be developed
360 independent of existing clinical data to ensure that the digital score does not inherit the
361 shortcomings of the clinical measure (e.g. restriction of range, reduced resolution of scale).
362 However, this requires independent longitudinal sensor datasets to build and validate such a
363 digital score (49). Since such data are not yet available, a provisional single summary
364 sensor-based measure, the 'PASADENA Digital Motor Score', reflecting global motor
365 function was developed. Data from a PASADENA-like PPMI cohort were used to inform
366 sensor feature selection for the PASADENA Digital Motor Score, as follows: MDS-UPDRS
367 Part II and III item-level scores which significantly declined in Year 1 of PPMI were identified
368 (n=21; whereby one item (posture) was not tested with the digital biomarker; final set of
369 MDS-UPDRS items = 20). A blinded subset of PASADENA data (n=157) was used to map
370 sensor feature data (aggregated over 2-week periods) onto each MDS-UPDRS item with the
371 blinded PASADENA population. The set of sensor features was used to predict the sum of
372 the 20 identified MDS-UPDRS items. PASADENA Digital Motor Scores were generated for
373 every two weeks of the study and submitted to linear random coefficient (i.e. slope) models
374 testing for differences in slopes between censored patients in each treatment group over the
375 26 two-week periods of the PASADENA study.

376

377 A second set of exploratory digital biomarker analyses comprised 17 individual pre-specified
378 sensor features, which were selected based on a previous communication that reported
379 cross-sectional correlations between sensor features and MDS-UPDRS scores (50) and
380 available literature. These individual sensor features were also analyzed with linear random
381 coefficient models testing for differences in slopes across treatment groups if the model's
382 residuals were normally distributed; if the residuals were not normally distributed, mixed
383 effects models with repeated measures were applied.

384

385 *Standard protocol approvals, registrations, and patient consents*

386 This study was conducted in full conformance with the International Conference on
387 Harmonization E6 guideline for Good Clinical Practice and the principles of the Declaration
388 of Helsinki, or the laws and regulations of the country in which the research was conducted,
389 whichever afforded the greater protection to the individual. The study protocol, Informed
390 Consent Forms, and any information given to the participant, were approved by the
391 Institutional Review Board or Ethics Committee (NCT03100149).

392 *Sample size justification*

393 A sample size of approximately 100 randomized participants per group (300 participants in
394 total for the three groups) was estimated, which allowed for a power of approximately 80% at
395 two-sided α -level of 20% to detect a three-point difference in MDS-UPDRS Total score
396 between groups from baseline at Week 52. The power calculation was based on simulations
397 of the mixed-effect model for repeated measures (MMRM) analysis planned for the primary
398 efficacy variable. Assessments performed while on any symptomatic therapy started after
399 randomization were not included in the analysis of the primary endpoint.

400
401 The assumptions on progression, variability, dropout rate and likelihood to start symptomatic
402 therapy within the first 52 weeks of treatment, with or without a MAO-B inhibitor as
403 background therapy, were derived from analyses based on the PPMI database and various
404 sources of information from the literature (46, 51). The percentage of patients defined as
405 non-evaluable at Week 52 was predicted to be 25% in the placebo group and 20% in the
406 treatment groups. This estimate included non-evaluable data from patients who prematurely
407 dropped out and/or started symptomatic therapy after randomization.

408
409 The sample size of 100 patients per arm also provided 76% power ($\alpha=20\%$, two sided) to
410 reject the null hypothesis, assuming a 37.5% reduction for the key secondary endpoint, the
411 DaT-SPECT signal loss at Week 52 and the pairwise comparison of each active dose arm
412 with placebo (46, 51).

413

414 *Covariate adjustment*

415 Analyses of efficacy endpoints (primary, secondary, and exploratory) included the following
416 covariates in the model: background therapy at baseline (MAO-B inhibitor treatment [yes vs.
417 no]), age group (<60 years vs. ≥ 60 years), sex (male vs. female), DaT-SPECT binding ratio
418 in the contralateral (to the clinically most affected side) putamen at baseline, and treatment
419 group (4500 mg prasinezumab, 1500 mg prasinezumab or placebo). For each continuous
420 endpoint the baseline of the endpoint variable was included in the model.

421 *Statistical analyses of primary efficacy endpoint*

422 Change in MDS-UPDRS Total score from baseline vs. placebo was analyzed using an
423 MMRM, with covariates described in the *Covariate adjustment* section as fixed effects. The
424 model also included baseline MDS-UPDRS Total score, week of treatment (as a categorical
425 factor), a treatment-by-week interaction term and an interaction term between baseline
426 MDS-UPDRS by week. An unstructured variance-covariance matrix was used to model the
427 random error. The model tested the null hypothesis of no treatment difference at a two-sided
428 α -level of 20% for the following comparisons:

- 429 • 4500 mg or 3500 mg (high dose) prasinezumab vs. placebo
- 430 • 1500 mg (low dose) prasinezumab vs. placebo.

431 All the assessments flagged on and after the “first symptomatic PD treatment date” (either
432 initiation of symptomatic PD treatment or a change to MAO-B inhibitor dose) were not
433 included in the analysis. The primary endpoint of MDS-UPDRS Total score (sum of Parts I,
434 II, and III) was re-analyzed with data from the two treatment arms pooled, and compared
435 with placebo as an exploratory endpoint.

436

437 *Statistical analyses of secondary and exploratory efficacy endpoints*

438 For the endpoints utilizing MDS-UPDRS Part IA, Part IB, Part I total, Part II total, Part III
439 total, Part III subscores, CGI-I, and PGI-C, the information collected after symptomatic PD
440 treatment was handled as for the primary analysis. The analysis of all other endpoints
441 included all the data available regardless of start of symptomatic PD treatment.

442

443 An analysis of covariance (ANCOVA) was used to analyze the change from baseline at
444 Week 52 in MoCA Total score and SE-ADL score with covariates described in the *Covariate*
445 *adjustment* section. The change (between baseline and Week 52) in DaT-SPECT striatal
446 binding ratio in the ipsilateral (to the clinically most affected side) putamen, was analyzed
447 using ANCOVA. Arterial spin labeling (ASL) MRI was performed at sites with the technical
448 capability. Effects are tested for in pre-specified regions of interest; striatum, caudate, and
449 putamen (ipsilateral, contralateral, and average were assessed for each region). Between-
450 group changes in ASL MRI over 1 year in regions of interest were also tested using
451 ANCOVAs.

452
453 The CGI-I was intended as a measure of change in health status from baseline CGI -
454 Severity of illness (CGI-S). For the CGI-I, patients were divided into one of two groups:
455 • 'Responders': Score of 1–4 (i.e. rated as "no change", "minimally improved", "much
456 improved" or "very much improved").
457 • 'Progressors': Score of 5–7 (i.e. rated as "minimally worse", "much worse" or "very
458 much worse").

459 The proportion of patients rated by CGI-I grouping at Week 24 and Week 52 was analyzed
460 using a logistic regression model. The estimated odds ratio for 'responders' and
461 'progressors' at Week 24 and Week 52 for treated patients compared with placebo were
462 calculated with 80% confidence interval. Analysis of the PGI-C followed the same
463 methodology outlined for the CGI-I above.

464
465 Time to worsening of motor or non-motor symptoms (of ≥ 3 -point change from baseline in
466 MDS-UPDRS Part I or Part II) and time to start of dopaminergic (levodopa or dopamine
467 agonist) treatment were plotted using a Kaplan-Meier survival plot and analyzed using a Cox
468 proportional hazards model to obtain a treatment difference between each of the
469 prasinezumab dose levels against placebo. A 3-point minimum change in MDS-UPDRS Part
470 II was chosen as this has been previously identified as the smallest change of score that is
471 clinically meaningful to patients (52).

472 473 *Subgroup analyses*

474 Subgroups with $\geq 20\%$ of patients from the modified intent-to-treat population at baseline
475 were analyzed. The model used for the primary endpoint was run in each subgroup,
476 excluding the subgroup being analyzed if that was a covariate (e.g. MAO-B inhibitors at
477 baseline [yes vs. no]).

478 The subgroup analyses were performed in the primary endpoint and the following
479 secondary/exploratory endpoints:

- 480 • MDS-UPDRS Part I
- 481 • MDS-UPDRS Part II
- 482 • MDS-UPDRS Part III Total score and subscores
- 483 • MDS-UPDRS sums of Part II and III
- 484 • DaT-SPECT striatal binding ratio in the ipsilateral (to the clinically most affected side)
485 putamen
- 486 • PASADENA Digital Motor Score
- 487 • MoCA score
- 488 • Composite time to event.

489 Subgroups included in analyses were:

- 490 • MAO-B inhibitors at baseline (yes vs. no)
- 491 • H&Y Stage at baseline (I vs. II)
- 492 • Rapid Eye Movement Sleep Behavior Disorder Screening Questionnaire (RBDSQ) at
493 baseline (RBDSQ ≥ 5 vs. < 5)
- 494 • Data-driven subphenotypes (Diffuse malignant vs. mild motor predominant vs.
495 intermediate) at baseline

- 496 • Alpha-synuclein skin (positive vs. negative) (staining by immunohistochemistry on
497 skin biopsy sections at baseline)
- 498 • DaT-SPECT striatal binding ratio in the ipsilateral (to the clinically most affected side)
499 (very abnormal vs. abnormal) putamen.

500

501 For the derivations of the data-driven subphenotypes, scales were classified into: motor
502 scales (MDS-UPDRS Part II and MDS-UPDRS-Part III) and non-motor scales (Scales for
503 Outcomes in Parkinson's Disease - Autonomic Dysfunction [SCOPA-AUT], RDBSQ and
504 MoCA). After each one of the scales had been divided into percentiles, the data-driven
505 subphenotypes were defined as follows:

- 506 • *Diffuse malignant*: Score on motor scales being greater than the 75th percentile; and
507 at least one score on a non-motor scale greater than the 75th percentile; or all three
508 non-motor scores greater than the 75th percentile
- 509 • *Mild motor predominant*: Motor and all non-motor scores less than the 75th percentile
- 510 • *Intermediate*: All those individuals not meeting criteria for other subtypes.

511 *Inclusion criteria for the PPMI cohort*

512 The design of this study and the assumptions for progression, variability, dropout rate and
513 likelihood to start symptomatic therapy within the first 52 weeks of treatment, with or without
514 a MAO-B inhibitor, were derived from analyses of data collected in the PPMI observational
515 clinical study. Details regarding the PPMI study have been previously published and are
516 available at ppmi-info.org (53, 54). Patients from the PPMI population were selected for
517 comparison with the PASADENA cohort using the following criteria, which align with the
518 PASADENA study criteria: to have at least two of the following: resting tremor, bradykinesia,
519 rigidity (must have either resting tremor or bradykinesia) and confirmation from imaging core
520 that DaT-SPECT screening was consistent with dopamine transporter deficit. Data were
521 downloaded in May 2020 and, from the total 423 individuals in the PPMI population, a cohort
522 of 336 participants were selected based on the above criteria. No individuals in the PPMI
523 cohort received MAO-B inhibitors at baseline.

524

525 *Statistical comparisons between PASADENA and PPMI cohorts*

526

527 The standardized mean difference (SMD) in prognostic scores was used to assess
528 differences between baseline data for the PASADENA and PPMI cohorts, and for the
529 PASADENA MAO-B inhibitor-treated vs. treatment-naïve patient groups. The SMD was
530 calculated as the absolute value in the difference in means of a covariate across the
531 treatment groups, divided by the pooled SD. SMDs larger than 0.25 indicate that the groups
532 were too different from one another for a reliable comparison of change from baseline in that
533 variable (55). Overall, 20 covariates were selected for the analysis, including demographic,
534 imaging and clinical assessment (MDS-UPDRS Part I, II and III) data.

535

536 **Results of baseline data analysis**

537 *Baseline PASADENA demographics*

538 A total of 443 patients were screened between June 2017 and November 2018 at 60 sites.
539 Overall, 127 patients failed screening due to not meeting certain inclusion and exclusion
540 criteria, such as brain DaT-SPECT screening consistent with PD, concomitant disease or
541 condition within 6 months of screening and MMSE ≤ 25 . Overall, 316 patients were enrolled
542 at 57 centers across the following five countries: United States (160 patients [50.6%]), Spain
543 (50 patients [15.8%]), France (65 patients [20.6%]), Germany (35 patients [11.1%]), and
544 Austria (6 patients [1.9%]). Of those patients enrolled into the PASADENA study, 115 (36%)
545 had received MAO-B inhibitor treatment at enrollment and 201 (64%) were treatment naïve.
546 The mean (SD) age of PASADENA patients was 59.9 (9.10) years and the population
547 included 213 (67.4%) men and 103 (32.6%) women, with a mean time from diagnosis of

548 10.11 (6.50) years and 238 (75.3%) individuals being H&Y Stage II. The mean (SD) MDS-
549 UPDRS Total score at baseline was 31.41 (12.78) and the mean total scores for the
550 individual parts were: Part I, 4.61 (3.83); Part II, 5.33 (4.04) and Part III, 21.47 (9.00). The
551 mean baseline DaT-SPECT striatal binding ratios for the PASADENA population were 0.80
552 (0.25) for the contralateral putamen and 1.06 (0.32) for the ipsilateral putamen.

553 *MAO-B inhibitor treated vs. treatment-naïve patients in the PASADENA population*

554 Within the PASADENA study population, patients treated with MAO-B inhibitors at baseline
555 were on average younger (58.2 [9.00] years vs. 60.8 [9.00] years, respectively; SMD:
556 -0.290) and had a longer time from diagnosis (11.96 [6.10] months vs. 9.06 [6.50] months,
557 respectively; SMD: 0.461) vs. the treatment-naïve group. MAO-B inhibitor-treated patients
558 also had a higher MoCA score vs. the treatment-naïve group (28.27 [1.96] vs. 27.65 [2.04],
559 respectively; SMD: 0.309). All other baseline characteristics were balanced between patients
560 who received a MAO-B inhibitor (n=115) and those who were treatment naïve (n=201)
561 (**Table 1 and Supplementary Figure 1**).

562 *PASADENA population vs. PPMI cohort, selected using PASADENA eligibility criteria*

563 When comparing the PASADENA population baseline characteristics with those of the PPMI
564 cohort, MDS-UPDRS mean scores were lower for the PASADENA population for Part I (4.61
565 [3.83] vs. 5.60 [3.93], respectively; SMD: 0.255) and Part IB (3.45 [2.78] vs. 4.33 [3.10],
566 respectively; SMD: 0.297) compared with the PPMI cohort. The PASADENA population had
567 a longer average time from diagnosis (10.11 [6.50] years vs. 6.44 [6.31] years, respectively;
568 SMD: -0.573) compared with the PPMI cohort. DaT-SPECT striatal binding ratios for the
569 PASADENA population for the contralateral putamen (0.80 [0.25] vs. 0.68 [0.27],
570 respectively; SMD: -0.445) and ipsilateral putamen (1.06 [0.32] vs. 0.96 [0.39], respectively;
571 SMD: -0.285) to the clinically most affected side were both higher compared with the PPMI
572 cohort. On average, PASADENA patients scored higher in MoCA (27.87 [2.03] vs. 27.24
573 [2.29], respectively; SMD: -0.291) and lower in SCOPA-AUT (8.05 [5.71] vs. 9.75 [6.23],
574 respectively; SMD: 0.284) scores compared with the PPMI cohort. All other baseline
575 characteristics were balanced between the PASADENA population and the PPMI cohort
576 (**Table 1 and Supplementary Figure 2**).

577 **Discussion**

578 PASADENA is the first Phase II study to test the efficacy of a monoclonal antibody binding
579 aggregated alpha-synuclein to slow disease progression in early PD. The PASADENA study
580 enrolled individuals diagnosed with early-stage PD, requiring that they be, *inter alia*, either
581 treatment naïve or on stable treatment with MAO-B inhibitors and have a DaT-SPECT-
582 confirmed dopaminergic deficit. In order for this Phase II proof-of-concept study to measure
583 the disease-modifying potential of prasinezumab within the study period of 1 year, it was
584 essential to define a population with a measurable rate of progression. The progression rate
585 may depend on baseline disease severity and other factors (56). Several previous studies
586 have reported that the progression rate in individuals with early PD is generally faster shortly
587 after diagnosis of PD and before the start of levodopa or dopamine agonist therapy usage
588 (46, 57). Individuals at this early stage of disease still have vulnerable dopaminergic neurons
589 and protecting them against the development of further alpha-synuclein pathology may
590 potentially slow motor disease progression. A 1-year treatment duration, if well powered, is
591 expected to be sufficient to demonstrate relevant between-group differences, resulting from
592 an effect of treatment on disease progression in individuals with early PD.

593 Current treatments for PD, such as levodopa, improve motor symptoms and aim to increase
594 dopamine levels, compensating for the dopaminergic cell and synaptic loss (58). It is
595 possible that the potential effects of treatment with a disease-modifying therapy on motor
596 symptoms in individuals with early PD might be masked by these powerful symptomatic

597 therapies (46, 54). People with early PD treated with MAO-B inhibitors have a reduced
598 likelihood of starting levodopa or dopamine agonists therapy compared with placebo, while
599 maintaining a relatively high progression rate (56, 57). Individuals with early PD who were
600 either treatment naïve or treated with a MAO-B inhibitor at baseline were, therefore, included
601 in Part 1 of the PASADENA study. The recruited PASADENA study population was also
602 similar to other early PD therapeutic trial populations (56, 59, 60).

603

604 In this study, a comparison of the baseline characteristics of PASADENA study participants
605 showed that those who received treatment with MAO-B inhibitors were younger with a longer
606 time from diagnosis compared with the treatment-naïve group; however, the two groups had
607 similar overall symptom severity at baseline. This observed similarity may be due to
608 improvement in MDS-UPDRS scores as a result of MAO-B inhibitor treatment, which
609 provides symptomatic relief to individuals with early PD by prolonging the action of dopamine
610 in the brain (61, 62). The younger age may be due to the fact that individuals with older
611 onset of PD usually receive levodopa rather than MAO-B inhibitors (63).

612 The design and assumptions of this study were informed from analyses of data collected in
613 the PPMI observational clinical study. Therefore, it was important to compare the baseline
614 characteristics of the PASADENA study population with the PPMI cohort to ensure the
615 assumptions made were also valid for the PASADENA population. The PASADENA
616 population and PPMI cohort showed different distributions for some demographic measures;
617 for example, more PASADENA participants were in H&Y Stage II (75% vs. 59%) and had on
618 average a 3.7-month-longer time from diagnosis than the PPMI cohort. However, the DaT-
619 SPECT striatal binding ratios for both the ipsilateral and contralateral putamen suggested
620 that the PASADENA population had a slightly less advanced disease in terms of severity
621 and potentially of progression.

622 Dose selection for the PASADENA trial was based on data from previous studies. In a
623 Phase I multiple-ascending-dose study (NCT02157714), individuals with mild-to-moderate
624 PD who received prasinezumab up to 60 mg/kg intravenously every 4 weeks reported no
625 serious or severe adverse events (11). Rapid-dose and time-dependent mean reductions
626 from baseline vs. placebo in free serum alpha-synuclein levels of up to 97% were reported in
627 trial participants after a single infusion at the highest dose ($P=0.002$), with similar reductions
628 after two additional infusions. Mean cerebrospinal fluid concentration of prasinezumab also
629 increased with dose, to approximately 0.3% relative to the concentration in serum across all
630 dose cohorts. Currently, assays to quantify engagement of prasinezumab with aggregated
631 forms of alpha-synuclein *in vivo* are not available. Thus, the dose selection for the Phase II
632 study was primarily based on human serum and cerebrospinal fluid pharmacokinetic data
633 extrapolation, and the relationship of these data with histopathological and functional
634 endpoints. The doses used in the PASADENA trial were selected to fall in the therapeutic
635 exposure range predicted from preclinical efficacy models; the high prasinezumab dose
636 (4500 mg for body weight ≥ 65 kg; 3500 mg for body weight < 65 kg) was selected to match
637 exposure at the 60 mg/kg dose in the multiple-ascending-dose study, and the 1500 mg
638 prasinezumab dose to yield exposure levels above those effective on alpha-synuclein
639 pathology in the mouse model, with sufficient separation between the two to enable
640 exposure response analyses. Both doses selected were expected to bind $>90\%$ of
641 pathological aggregated alpha-synuclein, as well as monomers, in the central nervous
642 system, thus both could show signal of efficacy on disease progression.

643 The effect of treatment with prasinezumab on clinical progression rate was determined using
644 the MDS-UPDRS and was supported with a panel of exploratory biomarkers assessing the
645 potential effects on PD pathology and progression of neuronal damage. The MDS-UPDRS is
646 comprised of four parts: Part I, Mentation, Behavior, and Mood; Part II, Activities of Daily
647 Living; Part III, Motor Examination; and Part IV, Complications of Therapy (48, 64). Each
648 parkinsonian sign or symptom is rated on a 5-point scale (ranging from 0 to 4), with higher

649 scores indicating more severe impairment (64). The MDS-UPDRS demonstrates good
650 reliability, validity and sensitivity to change over a range of measures of time from diagnosis
651 and severity (64). Previous studies in individuals with early PD have demonstrated a linear
652 increase in MDS-UPDRS of approximately 6–12 points per year following diagnosis and
653 prior to initiating symptomatic treatment (46, 54, 56, 57). A positive effect on MDS-UPDRS
654 scores may, therefore, indicate a potential effect on global PD progression of prasinezumab.
655 It is important to note that the increase in MDS-UPDRS scores in the treatment-naïve
656 population with early PD is derived from the Part III motor examination scores; this
657 population exhibits decline to a far lesser extent in activities of daily living (MDS-UPDRS Part
658 I) and motor problems in daily life (MDS-UPDRS Part II) (64).

659
660 A striatal dopamine transporter deficit on dopamine transporter imaging by DaT-SPECT
661 currently represents the most established imaging marker in PD, reflecting
662 neurodegeneration in key brain regions affected by alpha-synuclein pathology. Regardless
663 of dopaminergic treatment, individuals with early PD show the fastest decrease of DaT-
664 SPECT signal (i.e. loss of dopaminergic terminals) resulting in an inverse exponential
665 decline in striatal DaT-SPECT uptake values (65, 66). Therefore, DaT-SPECT will be used
666 as a secondary outcome measure in the PASADENA study to determine the disease-
667 modifying potential of prasinezumab.

668 Smartphones and smartwatches are built with high-quality sensors that, together with novel
669 software technologies, enable the remote, non-invasive, frequent and sensitive
670 measurement and analysis of motor and in PD (67-69). Digital monitoring of motor
671 symptoms using smartphones has been previously used in the Phase I study of
672 prasinezumab in individuals with PD (NCT02157714). Study participants completed a daily
673 battery of tests and carried the phone with them throughout the day for passive monitoring.
674 The study revealed high adherence and a strong correlation between smartphone sensor
675 data and clinical measures of motor signs and, notably, the detection of clinical
676 manifestations that were not apparent at site visits (70). A second version of this digital
677 biomarker approach was therefore implemented in the PASADENA study to maximize the
678 probability of detecting a potential therapeutic effect of prasinezumab and potentially provide
679 new insights into the functioning and behavior of individuals with PD.

680 A definitive diagnosis of PD can only be made *post mortem* as biomarker tools that detect
681 alpha-synuclein in the brain *in vivo* are not currently available (71). However, pathological
682 forms of alpha-synuclein have been detected in peripheral neurons present in skin biopsy
683 samples from individuals with PD; the degree of peripheral nerve pathology detected in
684 samples was found to correlate with disease severity (72, 73). Longitudinal skin biopsy
685 sampling has been implemented in the PASADENA study for the direct and *in vivo*
686 assessment of alpha-synuclein pathology, and its progression in response to treatment with
687 prasinezumab. Clinical data and samples, including skin biopsies, will be collected from
688 DaT-SPECT negative screen failure participants to determine whether the detection of
689 alpha-synuclein skin pathology may be used as a sensitive, specific, and less invasive tool to
690 diagnose PD.

691 **Conclusions**

692 The PASADENA Phase II study was designed to assess the safety and tolerability and
693 clinical effect on disease progression of prasinezumab in patients with early PD. This study
694 will focus on the effect of treatment in early PD, as disease progression is measurable and
695 predictable in this cohort and will not be masked by treatment with dopaminergic therapy.
696 The primary outcome measure will be supported by clinical measures and imaging to
697 investigate the potential physiological impact of treatment. In addition, novel digital
698 biomarkers will be used to assess potentially subtle effects of treatment on motor function in
699 individuals with PD.

700 **Data availability**

701 Qualified researchers may request access to individual patient-level data through the clinical
702 study data request platform (<https://vivli.org/>). Further details on Roche's criteria for eligible
703 studies are available here (<https://vivli.org/members/ourmembers/>). For further details on
704 Roche's Global Policy on the Sharing of Clinical Information and how to request access to
705 related clinical study documents, see here
706 (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm). Data used in the preparation of this article were
707 obtained from the Parkinson's Progression Markers Initiative (PPMI) database ([ppmi-](http://ppmi-info.org/data)
708 [info.org/data](http://ppmi-info.org/data)). For up-to-date information on the study, visit ppmi-info.org.

710 **Ethics statement**

711 Participants were identified for potential recruitment using site-specific recruitment plans
712 prior to consenting to take part in this study. Recruitment materials for participants had
713 received Institutional Review Board or Ethics Committee approval prior to use. The following
714 Institutional Review Boards ruled on ethics of the PASADENA study: Ethikkommission der
715 Medizinischen Universität Innsbruck, Innsbruck, Austria; Comité de Protection des
716 Personnes (CPP) Ouest IV, Nantes, France; Ethikkommission der Universität Leipzig and
717 Geschäftsstelle der Ethikkommission an der medizinischen Fakultät der Universität Leipzig,
718 Leipzig, Germany; Ethikkommission der Fakultät für Medizin der Technischen Universität
719 München, München, Germany; Ethikkommission der Universität Ulm (Oberer Eselsberg),
720 Ulm, Germany; Landesamt für Gesundheit und Soziales Berlin and Geschäftsstelle der
721 Ethik-Kommission des Landes Berlin, Berlin, Germany; Ethikkommission des FB Medizin der
722 Philipps-Universität Marburg, Marburg, Germany; Ethikkommission an der Medizinischen
723 Fakultät der Eberhard-Karls-Universität und am Universitätsklinikum Tübingen, Tübingen,
724 Germany; Ethikkommission an der Med. Fakultät der HHU Düsseldorf, Düsseldorf,
725 Germany; Ethikkommission der LÄK Hessen, Frankfurt, Germany; CEIm Hospital
726 Universitari Vall d'Hebron, Barcelona, Spain; Copernicus Group Independent Review Board,
727 Puyallup, Washington, USA; Western Institutional Review Board, Puyallup, Washington,
728 USA; The University of Kansas Medical Center Human Research Protection Program,
729 Kansas City, Kansas, USA; Oregon Health & Science University Independent Review Board,
730 Portland, Oregon, USA; Northwestern University Institutional Review Board, Chicago,
731 Illinois, USA; Spectrum Health Human Research Protection Program, Grand Rapids,
732 Michigan, USA; The University of Vermont Committees on Human Subjects, Burlington,
733 Vermont, USA; Beth Israel Deaconess Medical Center Committee on Clinical Investigations,
734 New Procedures and New Forms of Therapy, Boston, Massachusetts, USA; Vanderbilt
735 Human Research Protection Program Health, Boston, Massachusetts, USA; Vanderbilt
736 Human Research Protection Program Health, Nashville, Tennessee, USA; University of
737 Maryland, Baltimore Institutional Review Board, Baltimore, Maryland, USA; University of
738 Southern California Institutional Review Board, Los Angeles, California, USA; Columbia
739 University Medical Center Institutional Review Board, New York, New York, USA; University
740 of Southern California San Francisco Institutional Review Board, San Francisco, California,
741 USA; University of Pennsylvania Institutional Review Board, Philadelphia, Philadelphia,
742 USA; HCA - HealthOne Institutional Review Board, Denver, Colorado, USA. All Institutional
743 Review Boards gave ethical approval of the study.

744

745 **Funding statement**

746 The PASADENA study was funded by F. Hoffmann-La Roche Ltd.

747 PPMI, a public-private partnership, is sponsored by the Michael J. Fox Foundation (MJFF)
748 for Parkinson's Research and is co-funded by MJFF, AbbVie, Allergan, Amathus
749 Therapeutics, Avid Radiopharmaceuticals, Bial Biotech, Biogen Idec, BioLegend, Bristol-
750 Myers Squibb, Calico, Celgene, Denali Therapeutics Inc., 4D Pharma Plc, Eli Lilly and
751 Company, F. Hoffmann-La Roche Ltd, GE Healthcare, Genentech Inc, GlaxoSmithKline,
752 Golub Capital BDC, Handl Therapeutics, Insitro, Janssen Neuroscience, Lundbeck, Merck,

753 Meso Scale, Neurocrine Biosciences, Pfizer, Piramal, Prevail Therapeutics, Sanofi
754 Genzyme, Servier, Takeda, Teva Pharmaceutical Industries Ltd, UCB, Verily Life Sciences
755 and Voyager Therapeutics. Industry partners contribute to PPMI through financial and in-
756 kind donations and have a lead role in providing feedback on study parameters through the
757 Partners Scientific Advisory Board (PSAB). Through close interaction with the study, the
758 PSAB is positioned to inform the selection and review of potential progression markers that
759 could be used in clinical testing.

760

761 **Acknowledgments**

762 The authors thank all the subjects who participated in this study. The authors thank Sarah
763 Child of MediTech Media for providing medical writing support and Megan Speakman of
764 MediTech Media for medical editing assistance, which were funded by F. Hoffmann-La
765 Roche, in accordance with Good Publication Practice (GPP3) guidelines
766 (<http://www.ismpp.org/gpp3>).


767

768 **Author contributions**

GP, FGB, KIT, BM, WP, GGK, WMZ, DKN, SO, KM, MK and JS designed the study. GP,
FGB, KIT, BM, WP, AnB, AV, MM, AP, SO and TS were involved in data collection. GP, KIT,
BR, JAC, AV and MM analyzed the data. All authors were involved in data interpretation. GP
and AzB drafted the work. GP, FGB, KIT, BR, BM, WP, JAC, AP, TN, GGK, WMZ, HS, SO,
TS, KM, MK, JS, RD, PF, DU, and AzB critically revised important intellectual content. All
authors revised and gave input on the article. GP and AzB provided final approval of the
manuscript.

769 **Tables and figures**

770 **Figure 1. PASADENA study design schematic**



780 *Low dose = 1,500 mg, †High dose = 4,500 mg for ≥65 kg; 3,500 mg for <65 kg. DaT-SPECT, dopamine transporter imaging
 781 with single-photon emission computerized tomography; IV, intravenous; Q4W, every month.

782 **Figure 2. Schedule of activities in PASADENA Part 1**

	Screening	Baseline	Week 8	Week 16	Week 24	Week 32	Week 40	Week 48	Week 52
MDS-UPDRS	✓	✓	✓	✓	✓	✓	✓	✓	✓
MoCA	✓	✓			✓				✓
CGI-I					✓				✓
PGI-C					✓				✓
SE-ADL		✓			✓				✓
PDQ39*	✓				✓			✓	
SCOPA-AUT†	✓			✓			✓		✓
PDSS-2		✓			✓			✓	
DaT-SPECT	✓								✓
Digital biomarker‡	→								
MRI§	✓								✓
Skin biopsy	✓								✓
Modified H&Y	✓		✓	✓	✓	✓	✓	✓	✓

Only at screening: MMSE, RBDQ. Only at baseline: CGI-C.

783

784 *Parkinson's Disease Questionnaire – 39 (PDQ39) is at baseline, Week 20 and Week 48; †SCOPA-AUT (Scales
 785 for outcomes in Parkinson's disease autonomic dysfunction) is at baseline, Weeks 16, 28, 40 and 52. ‡Digital
 786 includes PASADENA Digital Motor Score, Patient Global Impression of Severity, Daily diary, Patient Assessment
 787 of Constipation Symptoms (PAC-SYM), EuroQoL-5D (EQ-5D) and Hospital Anxiety and Depression Scale
 788 (HADS). §Magnetic resonance imaging (MRI) includes safety, diffusion tensor imaging (DTI), resting state and
 789 arterial spin labeling (ASL).
 790 CGI-I, Clinical Global Impression of Change; CGI-I, Clinical Global Impression of Improvement; DaT-SPECT,
 791 dopamine transporter imaging with single-photon emission computerized tomography; H&Y, Hoehn & Yahr;
 792 MDS-UPDRS, Movement Disorder Society – Unified Parkinson's Disease Rating Scale; MMSE, Mini Mental
 793 State Examination; MoCA, Montreal Cognitive Assessment; PDSS-2, Parkinson's Disease Sleep Scale Revised
 794 Version 2; PGI-C, Patient Global Impression of Change; RBDSQ, Rapid Eye Movement Sleep Behavior Disorder
 795 Screening Questionnaire; SE-ADL, Schwab and England Activities of Daily Living.

796 **Figure 3. Schedule of activities in PASADENA Part 2**

	Week 56	Week 64	Week 72	Week 80	Week 88	Week 96	Week 100	Week 104	Withdrawal 3 months
MDS-UPDRS	✓	✓	✓	✓	✓	✓		✓	✓
MoCA	✓			✓				✓	✓
CGI-I	✓			✓				✓	✓
PGI-C	✓			✓				✓	✓
SE-ADL	✓			✓				✓	✓
PDQ39	✓							✓	✓
SCOPA-AUT	✓			✓				✓	✓
PDSS-2	✓			✓			✓		
DaT-SPECT	✓							✓	
Digital biomarker*	→								
MRI†								✓	
Skin biopsy								✓	

797 *Digital includes PASADENA Digital Motor Score, Patient Global Impression of Severity, Daily diary, Patient
 798 Assessment of Constipation Symptoms (PAC-SYM), EuroQol-5D (EQ-5D) and Hospital Anxiety and Depression
 799 Scale (HADS). †Magnetic resonance imaging (MRI) includes safety, diffusion tensor imaging (DTI), resting state
 800 and arterial spin labeling (ASL).
 801 CGI-I, Clinical Global Impression of Improvement; DaT-SPECT, dopamine transporter imaging with single-photon
 802 emission computerized tomography; MDS-UPDRS, Movement Disorder Society – Unified Parkinson’s Disease
 803 Rating Scale; MoCA, Montreal Cognitive Assessment; PDQ-39, Parkinson’s Disease Questionnaire – 39; PDSS-
 804 2, Parkinson’s Disease Sleep Scale Revised Version 2; PGI-C, Patient Global Impression of Change; SCOPA-
 805 AUT, Scales for outcomes in Parkinson’s disease autonomic dysfunction; SE-ADL, Schwab and England
 806 Activities of Daily Living.

807

808 **Figure 4. Table of digital measures included in the Roche Parkinson’s Disease Mobile**
 809 **Application v2**

ACTIVE TESTS										PASSIVE MONITORING			IN-CLINIC TESTS		
Bradykinesia			Tremor/ Bradykinesia		Tremor			Rigidity/ Postural Instability		Cognition	Bradykinesia and Activities of Daily Living			Balance	
Draw A Shape	Dexterity	Hand Turning	Speech	Phonation	Postural Tremor	Rest Tremor	Balance	U-Turn		Cognitive SDMT	Gait	Arm Swing & Tremor	Mobility & Sociability	Timed Up & Go	Berg Balance Scale
Bradykinesia Days (Every 2 nd Day)			Alternating		Tremor and Stability Days (Every 2 nd Day)					811	Daily	Daily	Daily	At selected visits	At selected visits
										812					
										814					
										815					

816 SDMT, Symbol Digit Modalities Test.

817

818

819

820

821

822

823 **Table 1. PASADENA; MAO-B inhibitor-treated vs. treatment-naïve patients, and**
 824 **PASADENA (all patients) vs. PPMI. Demographics and baseline disease characteristics**
 825 compared using the standardized mean difference

	PASADENA MAO-B inhibitor-treated patients (n=115)	PASADENA treatment-naïve patients (n=201)	SMD (CI)	PASADENA All patients (n=316)	PPMI PD patients (n=336)	SMD (CI)
Age, years mean (SD)	58.2 (9.00)	60.8 (9.00)	-0.290* (-0.520, -0.059)	59.90 (9.10)	61.30 (9.69)	0.166 (0.012, 0.320)
Gender Male, n (%) [†]	74 (64.3)	139 (69.2)	-0.048 (-0.156, 0.060)	213 (67.4)	220 (65.5)	-0.019 (-0.092, 0.053)
Years of education, mean (SD)	16.39 (5.20)	15.22 (4.80)	0.234 (0.006, 0.467)	15.65 (4.99)	15.53 (3.03)	-0.029 (-0.183, 0.125)
Time from diagnosis, months mean (SD)	11.96 (6.10)	9.06 (6.50)	0.461* (0.225, 0.689)	10.11 (6.50)	6.44 (6.30)	-0.573* (-0.730, -0.417)
H&Y Stage II, n (%) [†]	83 (72.2)	155 (77.1)	-0.049 (-0.150, 0.051)	238 (75.3)	197 (59.0)	-0.167 (-0.238, -0.096)
RBDSQ (SD)	3.51 (2.65)	3.43 (2.75)	0.031 (-0.199, 0.260)	3.46 (2.71)	4.14 (2.69)	0.250 (0.095, 0.405)
DaT-SPECT contralateral putamen (SD)	0.81 (0.24)	0.78 (0.25)	-0.102 (-0.331, 0.128)	0.80 (0.25)	0.68 (0.27)	-0.445* (-0.601, -0.289)
DaT-SPECT ipsilateral putamen (SD)	1.02 (0.30)	1.09 (0.33)	-0.194 (-0.421, 0.038)	1.06 (0.32)	0.96 (0.39)	-0.285* (-0.439, -0.129)
MoCA (SD)	28.27 (1.96)	27.65 (2.04)	0.309* (0.076, 0.539)	27.87 (2.03)	27.24 (2.29)	-0.291* (-0.446, -0.136)
SCOPA-AUT (SD)	7.71 (4.82)	8.25 (6.16)	-0.096 (-0.323, 0.136)	8.05 (5.71)	9.75 (6.23)	0.284* (0.128, 0.439)
MDS-UPDRS Total, mean (SD)	30.21 (11.96)	32.10 (13.20)	-0.150 (-0.378, 0.081)	31.41 (12.78)	32.63 (13.04)	0.094 (-0.059, 0.248)
MDS-UPDRS Part I, mean (SD)	4.49 (3.40)	4.68 (4.06)	-0.051 (-0.279, 0.180)	4.61 (3.83)	5.60 (3.93)	0.255* (0.100, 0.409)
MDS-UPDRS Part IA, mean (SD)	0.96 (1.54)	1.27 (1.67)	-0.195 (-0.422, 0.037)	1.16 (1.62)	1.27 (1.57)	0.071 (-0.083, 0.224)
MDS-UPDRS Part IB, mean (SD)	3.53 (2.50)	3.14 (2.93)	0.045 (-0.185, 0.273)	3.45 (2.78)	4.33 (3.10)	0.297* (0.142, 0.451)
MDS-UPDRS Part II, mean (SD)	5.19 (3.90)	5.41 (4.13)	-0.055 (-0.284, 0.174)	5.33 (4.04)	6.12 (4.20)	0.190 (0.036, 0.344)
MDS-UPDRS Part III, mean (SD)	20.53 (8.81)	22.01 (9.09)	-0.165 (-0.394, 0.065)	21.47 (9.00)	20.92 (8.88)	-0.062 (-0.216, 0.092)
MDS-UPDRS Part III Axial Symptoms, mean (SD) [‡]	0.77 (0.50)	0.78 (0.57)	-0.004 (-0.233, 0.225)	0.78 (0.54)	0.68 (0.71)	-0.153 (-0.307, 0.001)
MDS-UPDRS Part III Bradykinesia, mean (SD) [‡]	9.91 (5.60)	10.48 (5.49)	-0.102 (-0.331, 0.127)	10.27 (5.53)	10.60 (5.60)	0.059 (-0.095, 0.212)
MDS-UPDRS Part III Rigidity, mean (SD) [‡]	3.90 (2.58)	4.17 (2.83)	-0.103 (-0.331, 0.128)	4.07 (2.74)	3.86 (2.61)	-0.078 (-0.232, 0.075)
MDS-UPDRS Part III Resting Tremors, mean (SD) [‡]	2.71 (2.77)	3.12 (2.74)	-0.147 (-0.377, 0.082)	2.97 (2.75)	2.58 (2.42)	-0.151 (-0.305, 0.003)

826 *Indicates not balanced covariates (>0.25 SMD). [†]For binary variables the table shows the difference in
 827 proportions. [‡]Part III subscores are defined as: Bradykinesia (sum of item 3.4, finger tapping; item 3.5, hand
 828 movements; item 3.6, pronation-supination movements of hands; item 3.7, toe tapping; item 3.8, leg agility; item
 829 3.9, arising from chair; item 3.13, posture; and item 3.14, body bradykinesia); Rigidity (sum of item 3.3. [Neck,
 830 Upper Limbs and Lower Limbs]); Resting tremors (sum of item 3.17, rest tremor amplitude [Lip/Jaw, Upper Limbs
 831 and Lower Limbs] and item 3.18, constancy of tremor); and axial symptoms (sum of item 3.10, gait; item 3.11,
 832 freezing of gait; and item 3.12, postural stability). CI, confidence interval; DaT-SPECT, dopamine transporter
 833 single-photon emission computerized tomography; H&Y, Hoehn and Yahr; MAO-B, monoamine oxidase B; MDS-
 834 UPDRS, Movement Disorders Society – Unified Parkinson's Disease Rating Scale; MoCA, Montreal Cognitive
 835 Assessment; PD, Parkinson's disease; PPMI, Parkinson's Progression Markers Initiative; RBDSQ, Rapid Eye
 836 Movement Sleep Behavior Disorder Screening Questionnaire; SCOPA-AUT, Scales for outcomes in Parkinson's
 837 disease autonomic dysfunction; SD, standard deviation; SMD, standardized mean difference.

839 References

- 840 1. Verschuur CVM, Suwijn SR, Boel JA, Post B, Bloem BR, van Hilten JJ, et al. Randomized Delayed-
 841 Start Trial of Levodopa in Parkinson's Disease. The New England journal of medicine.
 842 2019;380(4):315-24.

- 843 2. Lang AE, Espay AJ. Disease Modification in Parkinson's Disease: Current Approaches, Challenges,
844 and Future Considerations. *Movement disorders : official journal of the Movement Disorder Society.*
845 2018;33(5):660-77.
- 846 3. Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson disease and the neurobiology of
847 axons. *Annals of Neurology.* 2010;67(6):715-25.
- 848 4. Jankovic J, Aguilar LG. Current approaches to the treatment of Parkinson's disease. *Neuropsychiatr*
849 *Dis Treat.* 2008;4(4):743-57.
- 850 5. Bonnet AM. Involvement of Non-Dopaminergic Pathways in Parkinson's Disease. *CNS Drugs.*
851 2000;13(5):351-64.
- 852 6. Giguere N, Burke Nanni S, Trudeau LE. On cell loss and selective vulnerability of neuronal
853 populations in Parkinson's disease. *Front Neurol.* 2018;9:455.
- 854 7. Lees AJ. The on-off phenomenon. *Journal of neurology, neurosurgery, and psychiatry.*
855 1989;Suppl:29-37.
- 856 8. Jenner P. Treatment of the later stages of Parkinson's disease - pharmacological approaches now
857 and in the future. *Transl Neurodegener.* 2015;4:3.
- 858 9. Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ. Quality of life and burden in caregivers for
859 patients with Parkinson's disease: concepts, assessment and related factors. *Expert Review of*
860 *Pharmacoeconomics & Outcomes Research.* 2012;12(2):221-30.
- 861 10. Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, et al. Update on
862 treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. *Mov*
863 *Disord.* 2019;34(2):180-98.
- 864 11. Jankovic J, Goodman I, Safirstein B, Marmon TK, Schenk DB, Koller M, et al. Safety and
865 Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-alpha-Synuclein Monoclonal
866 Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial. *JAMA neurology.*
867 2018;75(10):1206-14.
- 868 12. Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, et al. Passive immunization
869 reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy
870 body disease. *PloS one.* 2011;6(4):e19338.
- 871 13. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkman J, et al. Parkinson disease.
872 *Nature reviewsDisease primers.* 2017;3:17013.
- 873 14. Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Watson J, et al. Unified staging system for
874 Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor
875 dysfunction. *Acta Neuropathologica.* 2009;117(6):613-34.
- 876 15. Del Tredici K, Braak H. Review: Sporadic Parkinson's disease: development and distribution of
877 alpha-synuclein pathology. *Neuropathology and applied neurobiology.* 2016;42(1):33-50.
- 878 16. Shahmoradian SH, Lewis AJ, Genoud C, Hench J, Moors TE, Navarro PP, et al. Lewy pathology in
879 Parkinson's disease consists of crowded organelles and lipid membranes. *Nature neuroscience.*
880 2019;22(7):1099-109.
- 881 17. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in
882 Lewy bodies. *Nature.* 1997;388(6645):839-40.
- 883 18. Mahul-Mellier AL, Bartscher J, Maharjan N, Weerens L, Croisier M, Kuttler F, et al. The process of
884 Lewy body formation, rather than simply alpha-synuclein fibrillization, is one of the major drivers of
885 neurodegeneration. *Proceedings of the National Academy of Sciences of the United States of*
886 *America.* 2020;117(9):4971-82.
- 887 19. Rey NL, Steiner JA, Maroof N, Luk KC, Madaj Z, Trojanowski JQ, et al. Widespread transneuronal
888 propagation of α -synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson's disease.
889 *J Exp Med.* 2016;13(9):1759-78.
- 890 20. Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, et al. Pathological alpha-synuclein
891 transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. *Science (New York,*
892 *NY).* 2012;338(6109):949-53.

- 893 21. Games D, Seubert P, Rockenstein E, Patrick C, Trejo M, Ubhi K, et al. Axonopathy in an alpha-
894 synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-
895 terminal-truncated alpha-synuclein. *The American journal of pathology*. 2013;182(3):940-53.
- 896 22. Hansen C, Angot E, Bergstrom AL, Steiner JA, Pieri L, Paul G, et al. α -Synuclein propagates from
897 mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. *The*
898 *Journal of clinical investigation*. 2011;121(2):715-25.
- 899 23. Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, et al. Inclusion formation and
900 neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. *Proceedings of the*
901 *National Academy of Sciences of the United States of America*. 2009;106(31):13010-5.
- 902 24. Luk KC, Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, Lee VM. Intracerebral inoculation of
903 pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-
904 synucleinopathy in mice. *J Exp Med*. 2012;209(5):975-86.
- 905 25. Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A, et al. Exogenous alpha-
906 synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death.
907 *Neuron*. 2011;72(1):57-71.
- 908 26. Kim S, Kwon SH, Kam TI, Panicker N, Karuppagounder SS, Lee S, et al. Transneuronal Propagation
909 of Pathologic alpha-Synuclein from the Gut to the Brain Models Parkinson's Disease. *Neuron*.
910 2019;103(4):627-41 e7.
- 911 27. Rey NL, Bousset L, George S, Madaj Z, Meyerdirk L, Schulz E, et al. alpha-Synuclein
912 conformational strains spread, seed and target neuronal cells differentially after injection into the
913 olfactory bulb. *Acta Neuropathol Commun*. 2019;7(1):221.
- 914 28. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-
915 synuclein gene identified in families with Parkinson's disease. *Science (New York, NY)*.
916 1997;276(5321):2045-7.
- 917 29. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. Alpha-synuclein locus
918 triplication causes Parkinson's disease. *Science (New York, NY)*. 2003;302(5646):841.
- 919 30. Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, Pollak P, et al. Causal relation between
920 alpha-synuclein gene duplication and familial Parkinson's disease. *Lancet (London, England)*.
921 2004;364(9440):1169-71.
- 922 31. Kay DM, Factor SA, Samii A, Higgins DS, Griffith A, Roberts JW, et al. Genetic association between
923 alpha-synuclein and idiopathic Parkinson's disease. *American journal of medical genetics Part B,*
924 *Neuropsychiatric genetics : the official publication of the International Society of Psychiatric*
925 *Genetics*. 2008;147B(7):1222-30.
- 926 32. Bekris LM, Mata IF, Zabetian CP. The genetics of Parkinson disease. *J Geriatr Psychiatry Neurol*.
927 2010;23(4):228-42.
- 928 33. Devine MJ, Gwinn K, Singleton A, Hardy J. Parkinson's disease and alpha-synuclein expression.
929 *Movement disorders : official journal of the Movement Disorder Society*. 2011;26(12):2160-8.
- 930 34. Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, et al. Lewy bodies in grafted neurons in
931 subjects with Parkinson's disease suggest host-to-graft disease propagation. *Nat Med*.
932 2008;14(5):501-3.
- 933 35. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term
934 embryonic nigral transplants in Parkinson's disease. *Nat Med*. 2008;14(5):504-6.
- 935 36. Wilson H, Dervenoulas G, Pagano G, Koros C, Yousaf T, Picillo M, et al. Serotonergic pathology
936 and disease burden in the premotor and motor phase of A53T alpha-synuclein parkinsonism: a cross-
937 sectional study. *The Lancet Neurology*. 2019;18(8):748-59.
- 938 37. Knudsen K, Fedorova TD, Hansen AK, Sommerauer M, Otto M, Svendsen KB, et al. In-vivo staging
939 of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. *The*
940 *Lancet Neurology*. 2018;17(7):618-28.
- 941 38. Dehay B, Bourdenx M, Gorry P, Przedborski S, Vila M, Hunot S, et al. Targeting alpha-synuclein
942 for treatment of Parkinson's disease: mechanistic and therapeutic considerations. *The*
943 *Lancet Neurology*. 2015;14(8):855-66.

- 944 39. Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, et al. Effects of alpha-
945 synuclein immunization in a mouse model of Parkinson's disease. *Neuron*. 2005;46(6):857-68.
- 946 40. Games D, Valera E, Spencer B, Rockenstein E, Mante M, Adame A, et al. Reducing C-terminal-
947 truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in
948 Parkinson's disease-like models. *The Journal of neuroscience : the official journal of the Society for
949 Neuroscience*. 2014;34(28):9441-54.
- 950 41. Spencer B, Valera E, Rockenstein E, Overk C, Mante M, Adame A, et al. Anti-alpha-synuclein
951 immunotherapy reduces alpha-synuclein propagation in the axon and degeneration in a combined
952 viral vector and transgenic model of synucleinopathy. *Acta Neuropathol Commun*. 2017;5(1):7.
- 953 42. Tran HT, Chung CH, Iba M, Zhang B, Trojanowski JQ, Luk KC, et al. Alpha-synuclein
954 immunotherapy blocks uptake and templated propagation of misfolded alpha-synuclein and
955 neurodegeneration. *Cell reports*. 2014;7(6):2054-65.
- 956 43. Kallab M, Herrera-Vaquero M, Johannesson M, Eriksson F, Sigvardson J, Poewe W, et al. Region-
957 Specific Effects of Immunotherapy With Antibodies Targeting alpha-synuclein in a Transgenic Model
958 of Synucleinopathy. *Front Neurosci*. 2018;12:452.
- 959 44. Schenk DB, Koller M, Ness DK, Griffith SG, Grundman M, Zago W, et al. First-in-human
960 assessment of PRX002, an anti-alpha-synuclein monoclonal antibody, in healthy volunteers.
961 *Movement disorders : official journal of the Movement Disorder Society*. 2017;32(2):211-8.
- 962 45. PPMI. A landmark study of Parkinson's disease. 2018 [Available from: [https://www.ppmi-
963 info.org/](https://www.ppmi-info.org/)].
- 964 46. Simuni T, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Jennings D, et al. Longitudinal Change
965 of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers
966 Initiative Cohort. *Movement disorders : official journal of the Movement Disorder Society*.
967 2018;33(5):771-82.
- 968 47. ClinicalTrials.gov. NCT03100149: A study to evaluate the efficacy of prasinezumab
969 (RO7046015/PRX002) in participants with early Parkinson's disease (PASADENA) 2017 [updated
970 17/12/2019. Available from:
971 <https://clinicaltrials.gov/ct2/show/NCT03100149?term=prasinezumab&draw=2&rank=1>].
- 972 48. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement
973 Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS):
974 scale presentation and clinimetric testing results. *Movement disorders : official journal of the
975 Movement Disorder Society*. 2008;23(15):2129-70.
- 976 49. Taylor KI, Staunton H, Lipsmeier F, Nobbs D, Lindemann M. Outcome measures based on digital
977 health technology sensor data: data- and patient-centric approaches. *NPJ Digit Med*. 2020;3:97.
- 978 50. Lipsmeier F, Simillion C, Bamdadian A, Smith A, Schobel S, Gossens C, et al. Reliability, feasibility
979 and validity of a novel digital monitoring platform assessing cognitive and motor symptoms in
980 people with Stage I and II Huntington's disease (HD). *Neurotherapeutics*. 2019;16(4):1350-90.
- 981 51. Marek K, Chowdhury S, Siderowf A, Coffey CS, Caspell-Garcia CJ, Simuni T, et al. The Parkinson's
982 progression markers initiative (PPMI) - establishing a PD biomarker cohort. *Ann Clin Transl Neurol*.
983 2018;5(12):1460-77.
- 984 52. Horvath K, Aschermann Z, Kovacs M, Makkos A, Harmat M, Janszky J, et al. Minimal clinically
985 important differences for the experiences of daily living parts of movement disorder society-
986 sponsored unified Parkinson's disease rating scale. *Mov Disord*. 2017;32(5):789-93.
- 987 53. Parkinson Progression Marker I. The Parkinson Progression Marker Initiative (PPMI). *Prog
988 Neurobiol*. 2011;95(4):629-35.
- 989 54. Marek K, Chowdhury S, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, et al. The Parkinson's
990 progression markers initiative (PPMI) - establishing a PD biomarker cohort. *Ann Clin Transl Neurol*.
991 2018;5(12):1460-77.
- 992 55. Stuart EA, Lee BK, Leacy FP. Prognostic score-based balance measures can be a useful diagnostic
993 for propensity score methods in comparative effectiveness research. *J Clin Epidemiol*. 2013;66(8
994 Suppl):S84-S90 e1.

- 995 56. Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW, et al. A double-blind,
996 delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc
997 analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
998 *The Lancet Neurology*. 2011;10(5):415-23.
- 999 57. Parkinson Study G. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.
1000 *Arch Neurol*. 2002;59(12):1937-43.
- 1001 58. Kalia LV, Kalia SK, Lang AE. Disease-modifying strategies for Parkinson's disease. *Movement*
1002 *disorders : official journal of the Movement Disorder Society*. 2015;30(11):1442-50.
- 1003 59. Mollenhauer B, Trautmann E, Sixel-Doring F, Wicke T, Ebentheuer J, Schaumburg M, et al.
1004 Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort.
1005 *Neurology*. 2013;81(14):1226-34.
- 1006 60. A controlled trial of lazabemide (Ro 19-6327) in levodopa-treated Parkinson's disease. Parkinson
1007 Study Group. *Arch Neurol*. 1994;51(4):342-7.
- 1008 61. Teo KC, Ho SL. Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in
1009 Parkinson's disease. *Transl Neurodegener*. 2013;2(1):19.
- 1010 62. Qamar MA, Sauerbier A, Politis M, Carr H, Loehrer P, Chaudhuri KR. Presynaptic dopaminergic
1011 terminal imaging and non-motor symptoms assessment of Parkinson's disease: evidence for
1012 dopaminergic basis? *NPJ Parkinsons Dis*. 2017;3:5.
- 1013 63. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. *JAMA*.
1014 2014;311(16):1670-83.
- 1015 64. Holden SK, Finseth T, Sillau SH, Berman BD. Progression of MDS-UPDRS Scores Over Five Years in
1016 De Novo Parkinson Disease from the Parkinson's Progression Markers Initiative Cohort. *Movement*
1017 *disorders clinical practice*. 2018;5(1):47-53.
- 1018 65. Nandhagopal R, Kuramoto L, Schulzer M, Mak E, Cragg J, McKenzie J, et al. Longitudinal evolution
1019 of compensatory changes in striatal dopamine processing in Parkinson's disease. *Brain : a journal of*
1020 *neurology*. 2011;134(Pt 11):3290-8.
- 1021 66. Schwarz J, Storch A, Koch W, Pogarell O, Radau PE, Tatsch K. Loss of dopamine transporter
1022 binding in Parkinson's disease follows a single exponential rather than linear decline. *J Nucl Med*.
1023 2004;45(10):1694-7.
- 1024 67. Maetzler W, Domingos J, Srulijes K, Ferreira JJ, Bloem BR. Quantitative wearable sensors for
1025 objective assessment of Parkinson's disease. *Movement disorders : official journal of the Movement*
1026 *Disorder Society*. 2013;28(12):1628-37.
- 1027 68. Ossig C, Antonini A, Buhmann C, Classen J, Csoti I, Falkenburger B, et al. Wearable sensor-based
1028 objective assessment of motor symptoms in Parkinson's disease. *J Neural Transm (Vienna)*.
1029 2016;123(1):57-64.
- 1030 69. F. Lipsmeier IFG, D. Wolf, T. Kilchenmann, A. Scotland, J. Schjodt-Eriksen, W.Y. Cheng, J.
1031 Siebourg-Polster, L. Jin, J. Soto, L. Verselis, M. Martin Facklam, F. Boess, M. Koller, M. Grundman, M.
1032 Little, A. Monsch, R. Postuma, A. Gosh, T. Kremer, K. Taylor, C. Czech, C. Gossens, M. Lindemann.
1033 Successful passive monitoring of early-stage Parkinson's disease patient mobility in Phase I
1034 RG7935/PRX002 clinical trial with smartphone sensors. *MDS; Basel, Switzerland*2017.
- 1035 70. Lipsmeier F, Taylor KI, Kilchenmann T, Wolf D, Scotland A, Schjodt-Eriksen J, et al. Evaluation of
1036 smartphone-based testing to generate exploratory outcome measures in a phase 1 Parkinson's
1037 disease clinical trial. *Movement disorders : official journal of the Movement Disorder Society*.
1038 2018;33(8):1287-97.
- 1039 71. Jankovic J. Parkinson's disease: clinical features and diagnosis. *Journal of neurology,*
1040 *neurosurgery, and psychiatry*. 2008;79(4):368-76.
- 1041 72. Wang N, Gibbons CH, Lafo J, Freeman R. alpha-Synuclein in cutaneous autonomic nerves.
1042 *Neurology*. 2013;81(18):1604-10.
- 1043 73. Donadio V, Incensi A, Leta V, Giannoccaro MP, Scaglione C, Martinelli P, et al. Skin nerve alpha-
1044 synuclein deposits: a biomarker for idiopathic Parkinson disease. *Neurology*. 2014;82(15):1362-9.